The 20-Year Head Start: How Amprion Is Transforming Neurodiagnostics

In this episode, Dr. Russ Lebovitz, CEO of Amprion, explains why detecting misfolded proteins years before symptoms begin could completely reshape how we diagnose Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. He breaks down how early detection unlocks new possibilities for intervention, why alpha-synuclein is such a powerful biomarker, and what it really takes to commercialise a diagnostic platform in one of the toughest areas of biotech. Key Takeaways: 🔹Early detection is essential for slowing neurodegenerative diseases 🔹Misfolded proteins can appear up to 20 years pre-symptom 🔹Diagnostics commercialisation requires deep regulatory expertise 🔹Partnerships like Amprion’s with Mayo Clinic accelerate scaling 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.